PMID- 19034513
OWN - NLM
STAT- MEDLINE
DCOM- 20090528
LR  - 20211020
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 135
IP  - 6
DP  - 2009 Jun
TI  - Salvage therapy with topotecan in heavily pretreated ovarian cancer patients.
PG  - 815-21
LID - 10.1007/s00432-008-0517-9 [doi]
AB  - BACKGROUND: We showed feasibility and efficacy of topotecan in third or a higher 
      line of chemotherapy in heavily pretreated ovarian cancer (HPOC) patients. 
      METHODS: Between January 2004 and June 2007, 25 cases of HPOC were treated with 
      topotecan as 30-min infusion at the dose of 1.5 mg/m2 through 5 consecutive days 
      every 21 days. We assessed toxicity profile using NCI CTC and the response was 
      measured according to RECIST and CA-125 criteria described by Rustin. RESULTS: 
      Heavily pretreated ovarian cancer received at least two cycles of topotecan 
      (median 6, range 2-6) with prior chemotherapy lines (median 3, range 3-7). In 20 
      HPOC who met RECIST criteria results were as follows: PR, 6/20 (30%); NC, 7/20 
      (35%); PD, 7/20 (35%). Biochemical response was noted in 20 patients having ?15% 
      (3/20) of 75% and 20% (4/20) of 50% decline of CA-125. Time to progression was 
      median 6 months (95% CI: 4.06-6.18) and overall survival was median 9 months (95% 
      CI: 8.69-16.27). In multivariate analysis, primary optimal debulking and response 
      to primary chemotherapy (HR = 0.24, 95% CI: 0.08-0.69, P = 0.0084; HR = 0.38, 95% 
      CI: 0.14-0.98, P = 0.0448, respectively) were independent prognostic factors when 
      assessed in relation to salvage therapy with topotecan. We did not observe 
      difference in side effects after topotecan treatment among patients in relation 
      to the higher number of previously used chemotherapy line (3 vs. >3). 
      CONCLUSIONS: We state that topotecan is able to offer a control of ovarian 
      cancer, despite previous treatment, but reliable management is needed to 
      alleviate hematologic toxicity.
FAU - Bodnar, Lubomir
AU  - Bodnar L
AD  - Department of Oncology, Military Institute of the Health Services, 128 Szaserow 
      Street, Warsaw 00-909, Poland. lubo@esculap.pl
FAU - Wcislo, Gabriel
AU  - Wcislo G
FAU - Nasilowska, Anna
AU  - Nasilowska A
FAU - Szarlej-Wcislo, Katarzyna
AU  - Szarlej-Wcislo K
FAU - Gasowska-Bodnar, Agnieszka
AU  - Gasowska-Bodnar A
FAU - Smoter, Marta
AU  - Smoter M
FAU - Szczylik, Cezary
AU  - Szczylik C
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20081126
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Antineoplastic Agents)
RN  - 7M7YKX2N15 (Topotecan)
SB  - IM
MH  - Alopecia/chemically induced
MH  - Anemia/chemically induced
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Drug Administration Schedule
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Nausea/chemically induced
MH  - Neutropenia/chemically induced
MH  - Ovarian Neoplasms/*drug therapy/pathology/therapy
MH  - *Salvage Therapy
MH  - Survival Analysis
MH  - Topotecan/adverse effects/*therapeutic use
MH  - Treatment Outcome
MH  - Vomiting/chemically induced
EDAT- 2008/11/27 09:00
MHDA- 2009/05/29 09:00
CRDT- 2008/11/27 09:00
PHST- 2008/02/08 00:00 [received]
PHST- 2008/11/05 00:00 [accepted]
PHST- 2008/11/27 09:00 [pubmed]
PHST- 2009/05/29 09:00 [medline]
PHST- 2008/11/27 09:00 [entrez]
AID - 10.1007/s00432-008-0517-9 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2009 Jun;135(6):815-21. doi: 10.1007/s00432-008-0517-9. 
      Epub 2008 Nov 26.